Robert Brinson

Research Chemist

Brinson Group

Contact

Email: rbrinson@umd.edu

Call: (240) 314-6336

Education

  • Postdoctoral Fellow, National Cancer Institute, 2008
  • Postdoctoral Fellow, Joint National Institute of Standards and Technology and National Institutes of Health National Research Council, 2006-2007
  • Ph.D., Chemistry, Wake Forest University, 2005
  • B.A., Chemistry and Music, Houghton College, 2001

Profile

Dr. Robert Brinson uses biophysical measurements to define the structure and dynamics of nucleic acids, proteins, and glycoproteins, with a specific focus on biotherapeutics. In particular, he seeks to harmonize and to translate nuclear magnetic resonance (NMR) methods for biopharmaceutical applications and to push the limits of NMR methodologies to define the critical quality attributes of higher order structure for protein drug products.

CURRENT RESEARCH

2D-NMR Method Development for Biopharmaceutical Structural Assessment

Techniques for the facile characterization of higher order structure of biotherapeutics are in great demand by the pharmaceutical industry. NMR spectroscopy provides structural information about proteins at atomic resolution as individual peak positions in ‘fingerprint’ amide or methyl NMR spectra are sensitive to structure. These peaks can serve as spectral indicators for establishing consistency in drug manufacturing, assessing the stability of drug formulations, detecting process-related drug product variations, and determining biosimilarity to innovator reference products. However, limits on sensitivity, molecular size, sample volumes, and the perceived need for stable-isotope enrichment have restrained widespread use of NMR in the biopharmaceutical industry. Recent advances in NMR hardware, acquisition methods, and new approaches for data analyses have greatly ameliorated these limitations. Two-dimensional (2D) 1H-13C and 1H-15N correlated spectra can now be collected on biologics, including monoclonal antibodies (mAbs), at natural isotopic abundance. Furthermore, in collaboration with the Mathematical Analysis and Modeling Group at NIST, Dr. Brinson develops chemometric analyses for the extraction of meaningful information from many 2D spectra. Together, the researchers aim to develop best practices based on the type of analyses needed for a given protein therapeutic sample set.

Representative 13C methyl spectral map of the intact NISTmAb reference antibody at natural isotopic abundance. (Right) Structural model of the NISTmAb with all methyl groups highlighted as red spheres.

Harmonization of the 2D-NMR method through an International Interlaboratory Study

The NISTmAb Interlaboratory NMR Study is a joint effort among 25 organizations to evaluate the performance of 2D heteronuclear NMR for use in characterizing the high order structure of proteins, with the aim of supporting the use of NMR to characterize biologic therapeutics. Researchers in nine countries, with equal representation from industrial, governmental, and academic laboratories, acquired 451 1H-13C-methyl and 1H-15N-amide 2D NMR correlation spectra using different acquisition methods and instruments. Spectra were collected on both the Fab antibody domain derived from the IgG1κ NIST monoclonal antibody (NISTmAb) and a U-15N, 20%-13C labeled NIST-Fab system suitability sample. Chemometric analyses, using multivariate statistical methods, allowed benchmarking of the precision and robustness of the NMR measurements. The complete data package is available at www.ibbr.umd.edu/groups/nistmab-nmr.

Publications
2022
Interlaboratory Studies Using the NISTmAb to Advance Biopharmaceutical Structural Analytics.
Structural Fingerprinting of Short Interfering RNA Therapeutics by Solution Nuclear Magnetic Resonance Spectroscopy.
2021
Excipient Innovation Through Precompetitive Research.
Highly conserved s2m element of SARS-CoV-2 dimerizes via a kissing complex and interacts with host miRNA-1307-3p.
Practical Applications of NMR to Solve Real-World Problems.
Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics.
2020
Crystal Structure of a Bivalent Antibody Fab Fragment.
Principal component analysis for automated classification of 2D spectra and interferograms of protein therapeutics: influence of noise, reconstruction details, and data preparation.
Assessment of the Higher-Order Structure of Formulated Monoclonal Antibody Therapeutics by 2D Methyl Correlated NMR and Principal Component Analysis.
Best Practices in Utilization of 2D-NMR Spectral Data as the Input for Chemometric Analysis in Biopharmaceutical Applications.
Chemometric Outlier Classification of 2D-NMR Spectra to Enable Higher Order Structure Characterization of Protein Therapeutics.
2019
Structure and Dynamics of a Site-Specific Labeled Fc Fragment with Altered Effector Functions.
Characterization of the internal translation initiation region in monoclonal antibodies expressed in Escherichia coli.
2D J-correlated proton NMR experiments for structural fingerprinting of biotherapeutics.
Structural insights into DNA-stabilized silver clusters.
2018
Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics.
Platform development for expression and purification of stable isotope labeled monoclonal antibodies in Escherichia coli.
Non-Uniform Sampling for All: More NMR Spectral Quality, Less Measurement Time.
2017
Application of 2D-NMR with room temperature NMR probes for the assessment of the higher order structure of filgrastim.
2016
Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars.